Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Lymphoma: early-phase trial registry
88 of 330 indexed Lymphoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #21 of 28,707 conditions by registered trial count.
330 US clinical trials · 88 currently recruiting · #21 of 28,707 conditions by registered trial count
Lymphoma: 330 US clinical trials tracked, 88 recruiting.
Lymphoma is the subject of 330 registered US clinical trials on ClinicalTrials.gov, 88 of them currently open to new participants. 25 are in Phase 3-4 (later-stage) and 229 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 34 of these trials.
Enrollment posture brief
Registry condition lymphoma
OPEN 88 | RECR 27% | LATE 25 | EARLY 229 | RANK #21 | SPON 34
Volume-matched condition peers
Nearest open-share peer: Age-related Macular Degeneration (27% recruiting · 75 trials)
Lymphoma lists 88 open slots (27% of 330 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Lymphoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Lymphoma is recruiting below its size-band peers.
88 of 330 indexed trials (26.7%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Lymphoma trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 34 of 330 trials (10.3%). 116 distinct sponsors appear on at least one study for this condition label.
-
Most Lymphoma trials plan to enrol fewer than 100 people.
Median target enrolment is 50 among the 300 trials that report a genuine target (sentinel values excluded). 213 of those (71%) plan for fewer than 100 participants.
-
Lymphoma research is mostly interventional.
299 interventional and 31 observational studies make up this index (90.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
330 total, page 6 of 7
Vorinostat and Rituximab in Treating Patients With Indolent Non-Hodgkin Lymphoma
City of Hope Medical Center
NCT00720876
Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer
California Cancer Consortium
NCT00104923
Busulfan in Treating Children and Adolescents With Refractory CNS Cancer
Pediatric Brain Tumor Consortium
NCT00006246
Food Effect Study of Alisertib (MLN8237) in Participants With Advanced Solid Tumors or Lymphomas
Millennium Pharmaceuticals
NCT01898078
Y 90 Ibritumomab Tiuxetan &Rituximab Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Beth Israel Deaconess Medical Center
NCT00073957
Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment
City of Hope Medical Center
NCT00544284
Perillyl Alcohol in Treating Patients With Refractory Cancer
National Cancer Institute (NCI)
NCT00002862
Paclitaxel and Estramustine in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Fox Chase Cancer Center
NCT00021372
Sym023 (Anti-TIM-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas
Symphogen A/S
NCT03489343
Chemotherapy Given With Amifostine and Filgrastim in Treating Patients With Recurrent or Metastatic Cancer
Roswell Park Cancer Institute
NCT00003294
Immunotherapy Using Cyclosporine, Interferon Gamma, and Interleukin-2 After High-Dose Myeloablative Chemotherapy With Autologous Stem Cell Transplantation in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma
Children's Oncology Group
NCT00070187
Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma
UNC Lineberger Comprehensive Cancer Center
NCT01234467
ABT-888 in Patients With Refractory Solid Tumors or Hematologic Cancer
National Institutes of Health Clinical Center (CC)
NCT00387608
Alefacept in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma or Peripheral T-Cell Non-Hodgkin's Lymphoma
Mayo Clinic
NCT00438802
Circulating microRNAs as Disease Markers in Pediatric Cancers
Ann & Robert H Lurie Children's Hospital of Chicago
NCT01541800
CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant
New York Medical College
NCT01049854
Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)
M.D. Anderson Cancer Center
NCT01490723
Genetic Study in Patients Receiving Treatment for Hodgkin's Disease or Childhood Brain Tumor
Duke University
NCT00006342
Therapy of Chronic Lymphocytic Leukemia With Dasatinib (BMS-354825)
M.D. Anderson Cancer Center
NCT00364286
A Pharmacokinetic and Pharmacodynamic Study of DZ-002 in Patients With Advanced Solid Malignancies or Lymphoma
Da Zen Theranostics
NCT04970992
Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With B-cell Non-Hodgkin's Lymphoma That Has Relapsed Following Peripheral Stem Cell Transplantation
Jonsson Comprehensive Cancer Center
NCT00003963
Concurrent School Attendance And Cancer Therapy: The Experiences of 6-12 Year Old Pediatric Oncology Patients
St. Jude Children's Research Hospital
NCT01383473
Treatment of Macroglobulinemic Lymphoma With 2CdA, Cyclophosphamide and Rituximab
M.D. Anderson Cancer Center
NCT00667329
SAHA + CHOP in Untreated T-cell Non-Hodgkin's Lymphoma
M.D. Anderson Cancer Center
NCT00787527
Granzyme B PET Imaging Drug as a Predictor of Immunotherapy Response to Checkpoint Inhibitors
Cytosite Biopharma
NCT04169321
Aminocamptothecin in Treating Patients With T-cell Lymphoma
Yale University
NCT00002635
A Phase I, Open-Label, Multiple Ascending Dose Study of RRx-001 and Nivolumab
EpicentRx
NCT02518958
Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's Lymphoma
UNC Lineberger Comprehensive Cancer Center
NCT00334438
A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-263 (Navitoclax).
Abbott
NCT01021358
CD5789 in Early Cutaneous T-Cell Lymphoma (CTCL)
M.D. Anderson Cancer Center
NCT01804335
TCR-α/β and CD19 Depleted Stem Cell Grafts From Haplo Donors for HSCT in Relapsed Lymphoma
University of Wisconsin, Madison
NCT02652468
PET Imaging of Cancer Patients Using [18F]-SKI-249380, a Radiolabeled Dasatinib-Derivative
Memorial Sloan Kettering Cancer Center
NCT01916135
Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent Primary CNS Lymphoma
Memorial Sloan Kettering Cancer Center
NCT00082836
Carfilzomib With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
University of California, San Francisco
NCT02187133
Phase 2 Study of Bexxar in Relapsed/Refractory DLCL
Susan Knox
NCT00490009
Interferon Alfa in Treating Children With HIV-Related Cancer
Children's Oncology Group
NCT00002621
Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer
University of California, San Francisco
NCT00301951
Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
M.D. Anderson Cancer Center
NCT00005092
A Safety and Tolerability Study of PCI-24781 in Subjects With Cancer
Pharmacyclics
NCT01149668
Cellular Adoptive Immunotherapy in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma
City of Hope Medical Center
NCT00182650
Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer
University of California, San Francisco
NCT00304018
Bone Marrow Transplantation With Specially Treated Bone Marrow in Treating Patients With Hematologic Cancer That Have Not Responded to Previous Therapy
Dana-Farber Cancer Institute
NCT00005988
Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL)
Memorial Sloan Kettering Cancer Center
NCT02301364
Irinotecan Plus Cyclosporine and Phenobarbital in Treating Patients With Solid Tumors or Lymphoma
National Cancer Institute (NCI)
NCT00002759
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
Roswell Park Cancer Institute
NCT00003661
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Non-Hodgkin's Lymphoma
Fox Chase Cancer Center
NCT00003957
Mass Balance, Pharmacokinetics and Metabolism Study of Alisertib
Millennium Pharmaceuticals
NCT01714947
Idiotype Vaccine After Chemotherapy & Stem Cell Transplantation in Lymphoma With Failed Induction Chemotherapy
University of Nebraska
NCT00574886
Radiolabeled Monoclonal Antibody in Treating Patients With Previously Treated Large Cell Lymphoma
Case Comprehensive Cancer Center
NCT00028613
Photodynamic Therapy in Treating Patients With Lymphoma or Chronic Lymphocytic Leukemia
Roswell Park Cancer Institute
NCT00054171
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 119 |
| Phase 2 | 110 |
| Phase 3 | 22 |
| Phase 4 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Lymphoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Lymphoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Lymphoma page
330 registered trials, 88 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 88 Lymphoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Lymphoma trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Lymphoma condition card totals 330 registered trials; most-linked intervention cyclophosphamide; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.